PI-103

Catalog No.S1038

PI-103 Chemical Structure

Molecular Weight(MW): 348.36

PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (D) IGROV parental, shControl (two independent clones) and ShPKCiota (two independent clones) were treated with 5 μM GDC-0941 and 1.5 μM PI-103 for 24 hours and subjected to western blot analysis with the indicated antibodies. Each experiment was performed in triplicate.

    Oncogene, 2016, 35(19):2428-40. PI-103 purchased from Selleck.

    (A) MCF7 cells pre-treated with 100 nM siRNA for 72 h were re-seeded with normal growth media and grown overnight, then further transfected by 100nM of fresh siRNA. Twenty-(A) four hours after transfection, the cells were further treated with PI-103 for 24 h and the cell lysates were immunoblotted with the indicated antibodies. (B) Breast cancer cells carrying BRCA1 mutations were treated with 1 mM of PI-103 for 24h (left) or increasing amounts of PI-103 for 24 h (right). Cell lysates were analyzed by Western blotting with the indicated antibodies.

    Mol Carcinog 2012 52, 667-75 . PI-103 purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. PI-103 purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    Saraswati Sukumar of Johns Hopkins University School of Medicine PI-103 purchased from Selleck.

  • Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of PI-103 for 24 hours.

     

     

    Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.
Features The first potent, synthetic mTOR inhibitor.
Targets
p110α [3]
(Cell-free assay)
p110β [3]
(Cell-free assay)
p110δ [3]
(Cell-free assay)
p110γ [3]
(Cell-free assay)
DNA-PK [3]
(Cell-free assay)
2 nM 3 nM 3 nM 15 nM 23 nM
In vitro

PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-BE NHe2[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rJ[FAuQCEQvF2= M1:1bFI1NzR6L{eyJIg> MYjpcoR2[2W|IITpcYUuKGGwZDDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1cW:wIH;uJG5DKGOnbHyg[5Jwf3Sq NWfBSoFxOjZ{MkS2PFE>
SH-SY5Y M1;lXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPYVYIxNThizszN NIPnNGQzPC92OD:3NkBp NWDTPJZ5cW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> M1nNbFI3OjJ2Nkix
SH-SY5Y  M1HwWGFxd3C2b4Ppd{BCe3OjeR?= MYOxJO69VQ>? NFLyWZMxNjVvMkSgbC=> NHPCelN{\W6|aYTpfoV{KG6ndYLvZoxie3SxbXGgZ4VtdHNidH:g[I95d3K3YnnjbY4ucW6mdXPl[EBieG:ydH;zbZM> M4HOXVI3OjJ2Nkix
G 35 SC M1LZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXvNE4xPS1{MDFOwG0> NX7oUJF7OjRxN{KgbC=> NITOeJFFVVOR MYLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MoXQNlYyOjF{NUG=
G 38 SC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWewMlA2NTJyIN88US=> NUfsVFJVOjRxN{KgbC=> NH;sTopFVVOR MlywbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? NWrI[5lZOjZzMkGyOVE>
G 40 SC M1G1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGwMlA2NTJyIN88US=> MYqyOE84OiCq NXjw[mJLTE2VTx?= MonhbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? NUi5dXJVOjZzMkGyOVE>
G 35 DC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHNNE4xPS1{MDFOwG0> NXzvUIN5OjRxN{KgbC=> MUTEUXNQ M3TZN4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NFTI[YQzPjF{MUK1NS=>
G 38 DC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT2elUxNjB3LUKwJO69VQ>? MVOyOE84OiCq M3XEbmROW09? M3TsU4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NX[zO2ZoOjZzMkGyOVE>
G 40 DC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\YSlAvODVvMkCg{txO MnPrNlQwPzJiaB?= NVPPeG1{TE2VTx?= MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NHfUXXozPjF{MUK1NS=>
RD NYHyNYZCSXCxcITvd4l{KEG|c3H5 MYCxM|EvPS9{IN88US=> NXm2VpN1PzJiaB?= MVjpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MWqyOVc1QTN5OB?=
TE381.T M2\YUWFxd3C2b4Ppd{BCe3OjeR?= NXv6[2g6OS9zLkWvNkDPxE1? MVS3NkBp NEfCfWFqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? NI\yU4MzPTd2OUO3PC=>
RMS13 NVPTcFZISXCxcITvd4l{KEG|c3H5 NFfMXnIyNzFwNT:yJO69VQ>? MXu3NkBp Mmn2bY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> MVyyOVc1QTN5OB?=
RH30  NUXPXZBRSXCxcITvd4l{KEG|c3H5 NWTtb4E{OS9zLkWvNkDPxE1? MWq3NkBp NGLZc4ZqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? NUXRNlE3OjV5NEmzO|g>
VJ MWXBdI9xfG:|aYOgRZN{[Xl? MWmxM|EvPS9{IN88US=> NGi4dIk4OiCq Mn3QbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NX7k[2lbOjV5NEmzO|g>
HS578T NHvNdphE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV7SU41kOC1|IN88US=> MlzIO|IhcA>? M3;EfIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MmTVNlU4OjF2MUm=
BT549 MlyyR4VtdCCYaXHibYxqfHliQYPzZZk> NE\hb|QxNTNizszN NHzvV2E4OiCq NEHtfopqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NWjMZZZuOjV5MkG0NVk>
MDA-MB-231 NUHVSJRyS2WubDDWbYFjcWyrdImgRZN{[Xl? MlfGNE0{KM7:TR?= M2i0NlczKGh? NX;BclJIcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M2nHSlI2PzJzNEG5
MDA-MB-468 NXP1Wpp7S2WubDDWbYFjcWyrdImgRZN{[Xl? NFXVS5kxNTNizszN Mme0O|IhcA>? NYH1THo6cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NH\YeZQzPTd{MUSxPS=>
MDA-MB-436 NVG3OXhJS2WubDDWbYFjcWyrdImgRZN{[Xl? NWfZN5hIOC1|IN88US=> M3vkUVczKGh? MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MYCyOVczOTRzOR?=
SUM149PT MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYmwMVMh|ryP NIK5TZE4OiCq MV3pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NHSwWpIzPTd{MUSxPS=>
MDA-MB-468 NELIdm5HfW6ldHnvckBCe3OjeR?= NXzjNGZCOC5yMT2xNEDPxE1? NGWyRoQzPCCq MmfU[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? NIPBVYIzPTd{MUSxPS=>
MDA-MB-231 MljDSpVv[3Srb36gRZN{[Xl? NVvCcIZDOC5yMT2xNEDPxE1? NIew[JkzPCCq MYTkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh NFfRdZMzPTd{MUSxPS=>
HS578T NFrFTohHfW6ldHnvckBCe3OjeR?= M2TtblAvODFvMUCg{txO MU[yOEBp MYHkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh MWWyOVczOTRzOR?=
SW872 NUjw[lh3TnWwY4Tpc44hSXO|YYm= NXj4eWoyOC5yMT2wMlUh|ryP MYOyOEBp M1HaTJJm\HWlZYOgRWtVKHCqb4PwbI9zgWyjdHnvckApeEGNVDmgZY5lKDSHQmCxJJBpd3OyaH;yfYxifGmxbjCodFRGSlBzKTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NEjYOnAzPDZ7NU[zNi=>
SW982 M{niemZ2dmO2aX;uJGF{e2G7 NYT1eYV[OC5yMT2wMlUh|ryP NInaN5EzPCCq NHXH[4Jz\WS3Y3XzJGFMXCCyaH;zdIhwenmuYYTpc44hMHCDS2SpJIFv\CB2RVLQNUBxcG:|cHjvdplt[XSrb36gLJA1TUKSMTmgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> MlXjNlQ3QTV4M{K=
SW872 NYDmTpNNSXCxcITvd4l{KEG|c3H5 NEW2TZQxNjBzLUCuOUDPxE1? NH3oXFY1QCCq NW\MelI3cW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MoHONlQ3QTV4M{K=
SW982 MlzkRZBweHSxc3nzJGF{e2G7 MmrDNE4xOS1yLkWg{txO MWe0PEBp MmfHbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MYWyOFY6PTZ|Mh?=
AGS HG NGfrPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fS[mlEPTB;MD62PEDDuSByLkCzNUDPxE1? MkHRNlQ2QTd2N{i=
AGS LG NFznSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTOTWM2OD1yLkC1JOKyKDBwMECxJO69VQ>? M373dlI1PTl5NEe4
HGC27 HG NX7ZdmFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwM{igxtEhOC5yMkKg{txO MkD3NlQ2QTd2N{i=
HGC27 LG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEKgxtEhOC5yMESg{txO M1u0dFI1PTl5NEe4
MKN45 HG M3jWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S0e2lEPTB;MT6wNUDDuSByLkC1NUDPxE1? MnHuNlQ2QTd2N{i=
MKN45 LG MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPMbHhJUUN3ME2wMlg4KMLzIECuNFMxKM7:TR?= NEfPTlYzPDV7N{S3PC=>
NUGC4 HG NUDuVoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrMSFRjUUN3ME2xOE4xKMLzIEOuPVE{KM7:TR?= NIKybnAzPDV7N{S3PC=>
NUGC4 LG Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG5TWM2OD1zND6wJOKyKDVwM{KxJO69VQ>? NEjvTpczPDV7N{S3PC=>
A549 NVHJc3NkTnWwY4Tpc44hSXO|YYm= NGe1UlgxNjJ3L{CuOU8yKM7:TR?= NIHpeGYzPCCq NHTpVoJqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOuaXfoeIx6 MVqyOFM2OTR{NR?=
H460 MWHGeY5kfGmxbjDBd5NigQ>? NWO0c2JzOC5{NT:wMlUwOSEQvF2= NV\LUnhwOjRiaB?= NEXuN|BqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOuaXfoeIx6 M3jWPVI1OzVzNEK1
H661 M1jP[2Z2dmO2aX;uJGF{e2G7 NULBXo5HOC5{NT:wMlUwOSEQvF2= NXPTPI1WOjRiaB?= NVe5OoJ3cW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 NX;xVW01OjR|NUG0NlU>
SAS MV\GeY5kfGmxbjDBd5NigQ>? MlSzNE4zPS9yLkWvNUDPxE1? MVqyOEBp MUnpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NU\JO2tKOjR|NUG0NlU>
UT5 NHfZNVRHfW6ldHnvckBCe3OjeR?= NVm0VGlkOC5{NT:wMlUwOSEQvF2= NVLLO5lDOjRiaB?= NYjx[WNGcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 M3XQ[|I1OzVzNEK1
FaDu NFPaUpJHfW6ldHnvckBCe3OjeR?= NHPpW2sxNjJ3L{CuOU8yKM7:TR?= MWmyOEBp NVrWRWd5cW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 NFXF[pUzPDN3MUSyOS=>
RD MW\BdI9xfG:|aYOgRZN{[Xl? M17ldVEwOS53L{Kg{txO M4TCflczKGh? M3qyXWROW09? NV[2TZBkcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? NVTxOYNZOjN4OES5NlU>
TE671 NGLuSGpCeG:ydH;zbZMhSXO|YYm= MlzoNU8yNjVxMjFOwG0> M171[|czKGh? M3rKWmROW09? MV7pcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 MUKyN|Y5PDl{NR?=
RH30  NXX0OJhuSXCxcITvd4l{KEG|c3H5 M4n6VlEwOS53L{Kg{txO M324NlczKGh? NX[3cXJETE2VTx?= M{PsZYlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> MWWyN|Y5PDl{NR?=
RMS13 NIm3UY9CeG:ydH;zbZMhSXO|YYm= MmDzNU8yNjVxMjFOwG0> NInyOHc4OiCq MX;EUXNQ MVrpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 MknYNlM3QDR7MkW=
SUM149PT MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVKwMlMh|ryP M{TQfFczKGh? MmnT[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ MnTCNlM3ODFyN{S=
MDA-MB-468 M4ryU2NmdGxiVnnhZoltcXS7IFHzd4F6 NVHPNWg3OC5|IN88US=> M2T6VVczKGh? NE\ENmhmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? NHXTfZQzOzZyMUC3OC=>
MDA-MB-231 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH3BUVMxNjNizszN M4jKWFczKGh? NGfpV4RmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? MWmyN|YxOTB5NB?=
SY5Y M4WzOGZ2dmO2aX;uJGF{e2G7 MlnHNU42NzJwNT:1JO69VQ>? NILjW40zPCCq MVTpcoR2[2W|IFexxsBk\WyuLXP5Z4xmKGG{cnXzeEBidmRiYYDvdJRwe2m| MXuyN|M4QDN2MR?=
SKNBE(2c) M4XmXWZ2dmO2aX;uJGF{e2G7 NXvUelhOOS53L{KuOU82KM7:TR?= MmHuNlQhcA>? MWPpcoR2[2W|IFexxsBk\WyuLXP5Z4xmKGG{cnXzeEBidmRiYYDvdJRwe2m| M4rVb|I{Ozd6M{Sx
RD M{fjSmFxd3C2b4Ppd{BCe3OjeR?= M{DJZ|MhyrWP Mm\yNVIhcA>? NYHGbVQ2TE2VTx?= MYPz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= NIHzUFEzOzNyMEiwPS=>
TP5014 M{DTV2Fxd3C2b4Ppd{BCe3OjeR?= M4ftelMhyrWP MkPWNVIhcA>? MXLEUXNQ NE\XeYF{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NVjNU|dJOjN|MEC4NFk>
HT1080 MVvBdI9xfG:|aYOgRZN{[Xl? NGSwNZQ{KML3TR?= NHSzWYsyOiCq M4DtfmROW09? M120PJNmdnOrdHn6[ZMhWkRiY3XscJMhfG9iRF;YMYlv\HWlZXSgZZBweHSxc3nz MV2yN|MxODhyOR?=
A549 MnvzSpVv[3Srb36gRZN{[Xl? MmexNE0{NjNizszN M4LZR|czKGh? M3PWOIlv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? MmnKNlMzPTl3OUG=
HCC827 MV7GeY5kfGmxbjDBd5NigQ>? MXmwMVMvOyEQvF2= MV63NkBp MlzRbY5lfWOnczDjc41xdGW2ZTDkc5dvemWpdXzheIlwdiCxZjDwRWtV NFjlPWkzOzJ3OUW5NS=>
H3122 MmjwSpVv[3Srb36gRZN{[Xl? M2jpZ|AuOy5|IN88US=> NGXpNnE4OiCq M33qdYlv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? Mo\XNlMzPTl3OUG=
TALL-1 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOx5qCK|ryP NUTSW25IPyCm NEXUSFRl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NH71WoEzOzB|OEK3Ny=>
HPB-ALL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVix5qCK|ryP M1rkdFch\A>? MWLk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MXOyN|A{QDJ5Mx?=
DND41 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmx5qCK|ryP M1PVXFch\A>? MmX2[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M3jGeFI{ODN6Mkez
SUP-T1 M4XwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXsTVAy6oDLzszN MVW3JIQ> NILtfYJl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NIXlO4EzOzB|OEK3Ny=>
PEER NYDXVFB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqx5qCK|ryP MXW3JIQ> MXTk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M2\kbFI{ODN6Mkez
ALL-SIL NFjKXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfnVoxMOeLCid88US=> MYW3JIQ> MXHk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MVqyN|A{QDJ5Mx?=
KE37 NFfEOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X2e|HjiIoQvF2= NELybWI4KGR? NYC1Z3RQ\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NGHKbJUzOzB|OEK3Ny=>
Karpas-45 NG\j[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHLNgKBkc7:TR?= NFW0O3k4KGR? MVzk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M4The|I{ODN6Mkez
RPMI-8402 MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofrNgKBkc7:TR?= NX;OZ3pFPyCm M1nEe4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NVyxWIR{OjNyM{iyO|M>
Jurkat NUXDUo1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LVfFHjiIoQvF2= M12ySVch\A>? NFHHZ41l\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MonhNlMxOzh{N{O=
MOLT-4 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LlWVHjiIoQvF2= NG[xWFY4KGR? NF\GVYVl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NFLZW4szOzB|OEK3Ny=>
PF-382 M2DSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17YdVHjiIoQvF2= NVXvSJRMPyCm MXrk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MnXuNlMxOzh{N{O=
CCRF-CEM NYG3R5JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKx5qCK|ryP MYe3JIQ> NUC4c2dy\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MYWyN|A{QDJ5Mx?=
LOUCY MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITpN2Qy6oDLzszN Mm[4O{Bl M4W5[IRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MV6yN|A{QDJ5Mx?=
MOLT-16 NXvSU2pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[x5qCK|ryP NIPxPZA4KGR? NVn3WmF5\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MXWyN|A{QDJ5Mx?=
MM1S MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCwMVIh|ryP M2nZblI1KGh? NUXLVHBpUUN3ME2wMlUh|ryP NEfB[3YzOjh{OUKzOC=>
NCI-H929 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSwMVIh|ryP M3XO[|I1KGh? M{jCdGlEPTB;MD6yOUDPxE1? MoDwNlI5Ojl{M{S=
KMS12-BM  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKwMVIh|ryP MlrWNlQhcA>? MmrFTWM2OO,:nkKg{txO M2rIPFIzQDJ7MkO0
MDA-MB-436 MXTGeY5kfGmxbjDBd5NigQ>? MU[xJO69VQ>? NWPmVpdZOjRiaB?= NFTCR2Jz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU MV[yNlQ5QDV7MB?=
SUM149PT MlvtSpVv[3Srb36gRZN{[Xl? NETZcFAyKM7:TR?= NWjZcXBOOjRiaB?= NV\2b2hiemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MXGyNlQ5QDV7MB?=
SUM1315MO2 NHjV[VJHfW6ldHnvckBCe3OjeR?= MknRNUDPxE1? MoXuNlQhcA>? MXTy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MWWyNlQ5QDV7MB?=
HCC1937 M{\QZmZ2dmO2aX;uJGF{e2G7 NXPX[m8yOSEQvF2= NGfVO|kzPCCq MnO2doVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= M{TaflIzPDh6NUmw
HCC827 NVTEPVVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUewMVMh|ryP NVzsSplmPzJiaB?= NVHWUWJwUUN3ME2wMlMh|ryP NWW3VJZnOjF{MkC0O|Q>
PC-9  M3i1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrEfYUxNTNizszN MUW3NkBp NFfGNIJKSzVyPUCuPEDPxE1? NVvwenRGOjF{MkC0O|Q>
LN229 Mn7uSpVv[3Srb36gRZN{[Xl? M{L6V|Eh|ryP MmrCOFghcA>? MnPIbY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? NX;CO2txOjFyNkK5PVM>
U87 NXTZe4ppTnWwY4Tpc44hSXO|YYm= M1W4W|Eh|ryP MWO0PEBp NW\1TJlycW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= M2H3PFIyODZ{OUmz
U373 MojNSpVv[3Srb36gRZN{[Xl? MoLtNUDPxE1? NVexSY1mPDhiaB?= NHK4OXdqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w M1fHZ|IyODZ{OUmz
SF767 MW\GeY5kfGmxbjDBd5NigQ>? M3LLWFEh|ryP M2nMSVQ5KGh? MnjmbY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? M2W1T|IyODZ{OUmz
Mel-Juso NHzu[XRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlX6NE4xOeLCk{Gw5qCK|ryP MYC3NkBp M17ZOolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NUfxcWpKOjFyNEi3PFU>
518A2  MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYGwMlAy6oDVMUFihKnPxE1? NXf2U|JwPzJiaB?= MX\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXT2OINNOjFyNEi3PFU>
Mel-Juso  NGq4b4ZHfW6ldHnvckBCe3OjeR?= MnPCNE4xODIkgKOx5qCK|ryP MkDRNlQhcA>? MXHzeZBxemW|c3XzJJBpd3OyaH;yfYxifGmxbjDv[kBxcG:|cHjheIllgWxiaX7vd4l1d2xiMz3rbY5ie2ViZH;3cpN1emWjbTD0ZZJo\XS| M{TZOFIyODR6N{i1
518A2 NELm[4hHfW6ldHnvckBCe3OjeR?= M{njWFAvODBz4pETNgKBkc7:TR?= NX3TUIdZOjRiaB?= M4fXUpN2eHC{ZYPz[ZMheGixc4Doc5J6dGG2aX;uJI9nKHCqb4PwbIF1cWS7bDDpco9{cXSxbDCzMYtqdmG|ZTDkc5dve3S{ZXHtJJRiemendIO= M4rkS|IyODR6N{i1
PC3  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L4OVI1cA>? NFKweWxIUTVywrC9JFExOCCwTR?= M3fPTFIxPTVzME[x
U87MG NVjEVYg1TnWwY4Tpc44hSXO|YYm= NH;5PWkxNjFvMTFOwG0> MnLsNlTjiImqwrC= NXfO[pM{TE2VTx?= MYHpcohq[mm2czDQTVNMNW2nZHnheIVlKHOrZ37hcIlv\w>? NVKyR5Z[OTl4M{O2PFM>
U138MG MnrJSpVv[3Srb36gRZN{[Xl? NVyyb2p7OC5zLUGg{txO NH6zO3UzPOLCiXlCpC=> MnziSG1UVw>? Mn3QbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? NUK2dYdpOTl4M{O2PFM>
U118MG M3jnSmZ2dmO2aX;uJGF{e2G7 MoDYNE4yNTFizszN MoPYNlTjiImqwrC= NIXxeGJFVVOR NHT2V4JqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= Moe4NVk3OzN4OEO=
U87MG NUL2TGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMUSg{txO NIPNZnAyQTV6NEKyOy=>
IGROV-1 M120RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwME[g{txO MUWxPVU5PDJ{Nx?=
DETROIT562 NX\FbYtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUThPWNHUUN3ME2wMlE{KM7:TR?= NEOzd4syQTV6NEKyOy=>
PC3  M{HZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DpPWlEPTB;MD6xNEDPxE1? NV\FNZdsOTl3OESyNlc>
SKOV-3 NXjtW|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHLUVU1UUN3ME2wMlEzKM7:TR?= NXGzdo9JOTl3OESyNlc>
HUVEC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEig{txO M4TBXFE6PTh2MkK3
UCH-1  M3;OdWZ2dmO2aX;uJGF{e2G7 MUSwMVUh|ryP MonibY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCkb4ToJGFMXCCjbnSgcXRQWiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXz6fooyOTl3Mki0OFE>
UCH-1  MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnr[oIxNjBzLUGwJO69VQ>? M1;sfVYh\A>? NI\ndJNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHTvd4Uh\GWyZX7k[Y51dHl? NELtcm4yQTV{OES0NS=>
UCH-1  NYHUV4NCSXCxcITvd4l{KEG|c3H5 Ml\SNE4yNTFyIN88US=> M4DNVFI1KGh? MmHGSG1UVw>? MYLpcoR2[2W|IHHwc5B1d3Orcx?= NUDEdWx7OTl3Mki0OFE>

... Click to View More Cell Line Experimental Data

In vivo When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]

Protocol

Kinase Assay:[3]
+ Expand

Enzyme Assays:

Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.
Cell Research:[2]
+ Expand
  • Cell lines: U87MG cells
  • Concentrations: 0.5 μM
  • Incubation Time: 24 hours
  • Method: U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
  • Formulation: 50% DMSO
  • Dosages: 5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 24 mg/mL (68.89 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 348.36
Formula

C19H16N4O3

CAS No. 371935-74-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy PI-103 | PI-103 supplier | purchase PI-103 | PI-103 cost | PI-103 manufacturer | order PI-103 | PI-103 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID